[Edaily Reporter KIM JI-WAN ] BL Pharmtech(065170)is accelerating its overseas commercialization efforts by establishing a series of collaborative partnerships with global pharmaceutical companies and investment firms at the “Bio International Convention 2026” (Bio USA). The company announced on the 2nd that it has signed non-disclosure agreements (NDAs) with several global companies and agreed to share follow-up data.

BL Pharmtech stated that during the event, it held partnering meetings with multinational pharmaceutical companies and investment firms, focusing on discussions regarding joint research and licensing (L/O) of “ML301,” the company’s core pipeline—an anticancer drug based on the “Molecular Glue Degrader” technology.

In particular, given the high level of interest in the Molecular Glue platform technology, concrete follow-up actions with global pharmaceutical and biotech companies are expected.

The Chief Scientific Officer (CSO) and Head of Business Development (BD) at a global pharmaceutical company—which is supporting BL Pharmtech’s technology development through the Bio Venture Incubation Program—gave a positive assessment of the potential for a license-out (L/O) of BL Pharmtech’s preclinical and early-clinical pipeline. The two companies plan to meet at the U.S. headquarters this October to discuss development progress and future collaboration plans.

The Chief Business Development Officer (BD) of a global biotech company specializing in anticancer drugs expressed strong interest in the molecular glue-based anticancer drug project currently under development by BL Pharmtech.

The two companies agreed to share confidential data after signing a non-disclosure agreement (NDA) and to conduct an in-depth review of the potential for technology licensing.

A French pharmaceutical company also took note of the potential to develop BL Pharmtech’s anticancer drug candidate into a small-molecule treatment for brain tumors. With a view toward future technology licensing (license-out), the two companies agreed to sign an NDA and share development status and research data.

Strategic consulting and the establishment of an investment network for global market entry also yielded positive results.

A U.S.-based firm specializing in new drug development incubation and business development consulting agreed to actively support BL Pharmtech in maximizing the value of its technology assets and identifying global partners through infrastructure and asset matching services.

Given the firm’s extensive experience in technology licensing with major global pharmaceutical companies, the likelihood of an early preclinical-stage license-out for BL Pharmtech’s project is expected to increase. BL Pharmtech plans to provide detailed research data and discuss specific collaboration plans following the conclusion of Bio USA.

The company has also established a foundation for collaboration with a major UK investment firm and a global biotech company specializing in anticancer drugs. The firm expressed its willingness to provide support during the translational research phase prior to clinical trials by leveraging its clinical network in the UK. The two companies agreed to share detailed data and discuss specific collaboration models after signing an NDA.

Opportunities for joint development with domestic companies are also expected to expand.

Domestic new drug development companies showed strong interest in securing a molecular adhesive pipeline that is expected to generate synergies with existing anticancer drugs. Accordingly, the companies agreed to continue follow-up discussions focused on joint research and technology collaboration plans.

A representative from BL Pharmtech stated, “This year’s Bio USA was a meaningful event that confirmed the innovation and global competitiveness of our molecular adhesive-based anticancer drug pipeline and early-stage development assets,” adding, “We will do our utmost to swiftly sign non-disclosure agreements (NDAs) with the global companies we met with, share research data, and generate tangible business results such as joint research and early-stage technology exports.”